C. Seynaeve

1.7k citations
37 papers · 668 · h-index 16

Impact in

  • Oncology top 10%
    • Cancer Treatment and Pharmacology
    • HER2/EGFR in Cancer Research
  • Cancer Research
    • Breast Cancer Treatment Studies

Papers in

Co-authors
Jaap Verweij (11 shared papers)M. Bontenbal (6 shared papers)PHM de Mulder (2 shared papers)Ronald de Wit (2 shared papers)J.G.M. Klijn (5 shared papers)Rolf H. Sijmons (2 shared papers)Aad Tibben (3 shared papers)Iris van Oostrom (2 shared papers)
Journals
European Journal of Cancer (7 papers)Cancer Research (3 papers)Journal of Clinical Oncology (2 papers)Annals of Oncology (2 papers)Acta Oncologica (1 paper)
Partner nations
NetherlandsUnited StatesUnited Kingdom

In The Last Decade

C. Seynaeve

36 papers receiving 635 citations

Peers

C. Seynaeve
Comparison fields: 5 of 78
  • Oncology 237
  • Cancer Research 129
  • Genetics 180
  • Pulmonary and Respiratory Medicine 130
  • Gastroenterology 22
Replace Winston Ueno with:
Winston Ueno United States
Anni Ravnsbæk Jensen Denmark
Hye Sook Han South Korea
Kentaro Nakao Japan
Erna Busch United States
Jill D. Trimbath United States
A.M. Thompson United Kingdom
Sergio Di Pietro Italy
Rakesh Chopra India
Anne S. Quante Germany
C. Seynaeve relative to Winston Ueno United States Winston Ueno's profile →
Citations per field
00.5×5×10×15×19×
Winston Ueno · 1×
Citations per year

Countries citing papers authored by C. Seynaeve

Since Specialization
Citations

This map shows the geographic impact of C. Seynaeve's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Seynaeve with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Seynaeve more than expected).

Fields of papers citing papers by C. Seynaeve

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Seynaeve. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Seynaeve. The network helps show where C. Seynaeve may publish in the future.

Co-authors

The 25 scholars most cited alongside C. Seynaeve, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with C. Seynaeve Line = papers co-authored together C. Seynaeve links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 37 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study
British Journal of Cancer ·(unknown), C. Seynaeve, Jan C. Schuller, K. Buser, H Porteder, S Van Belle, P. Sevelda, D Christmann, M Schmidt, Henry C Kitchener, D. Paes, PHM de Mulder
199274
2
Family system characteristics and psychological adjustment to cancer susceptibility genetic testing: a prospective study
Clinical Genetics ·Iris van Oostrom, Hanne Meijers‐Heijboer, H.J. Duivenvoorden, A Bröcker-Vriends, CJ van Asperen, Rolf H. Sijmons, C. Seynaeve, AR Van Gool, J.G.M. Klijn, Aad Tibben
200663
3
Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane
Breast Cancer Research and Treatment ·Carolien H. Smorenburg, M. Bontenbal, C. Seynaeve, C. van Zuylen, Gerda de Heus, Jaap Verweij, Ronald de Wit
200163
4
Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer.
Cancer Research ·SE Jones, C. Seynaeve, Annette Hasenburg, D Rae, Jean-Michael Vannetzel, Robert Paridaens, Christos Markopoulos, Yasuo Hozumi, Hein Putter, E.T.M. Hille, D.G. Kieback, Lina Asmar, Jan Smeets, R. Urbanski, JM Bartlett, CJ van de Velde
200953
5
A phase II study of ET-743/trabectedin (`Yondelis') for patients with advanced gastrointestinal stromal tumours
European Journal of Cancer ·Jean‐Yves Blay, Axel Le Cesne, Jaap Verweij, Michelle Scurr, C. Seynaeve, Sylvie Bonvalot, Pancras C.W. Hogendoorn, J. Jimeno, V. Evrard, M. van Glabbeke, Ian Judson
200444
6
Experience of parental cancer in childhood is a risk factor for psychological distress during genetic cancer susceptibility testing
Annals of Oncology ·Iris van Oostrom, Hanne Meijers-Heijboer, H.J. Duivenvoorden, A Bröcker-Vriends, Christi J. van Asperen, Rolf H. Sijmons, C. Seynaeve, Arthur R. Van Gool, J.G.M. Klijn, Aad Tibben
200636
7
Outcomes of First-Line Chemotherapy in Patients with Advanced or Metastatic Leiomyosarcoma of Uterine and Non-Uterine Origin
Sarcoma ·Astrid W. Oosten, C. Seynaeve, P.I.M. Schmitz, Michael A. den Bakker, Jaap Verweij, Stefan Sleijfer
200932
8
Five Years of Exemestane as Initial Therapy Compared to 5 Years of Tamoxifen Followed by Exemestane: The TEAM Trial, a Prospective, Randomized, Phase III Trial in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer.
Cancer Research ·Daniel Rea, Annette Hasenburg, C. Seynaeve, SE Jones, J.M. Vannetzel, Robert Paridaens, Christos Markopoulos, Yasuo Hozumi, Hein Putter, E.T.M. Hille, Lina Asmar, R. Urbanski, C. van de Velde, John M.S. Bartlett, Jan Smeets, D.G. Kieback
200931
9
Randomized Phase II Study of Docetaxel versus Doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: A Study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
International Journal of Clinical Oncology ·Jaap Verweij, S.M. Lee, W. Ruka, J. Buesa, Robert L. Coleman, Q.G.C.M. van Hoesel, C. Seynaeve, Eugenio Donato Di Paola, M. van Glabbeke, D. Tonelli, Ian Judson
200030
10
Relevant impact of central pathology review on nodal classification in individual breast cancer patients
Annals of Oncology ·J.H.M.J. Vestjens, Manon J. Pepels, Maaike de Boer, George F. Borm, Carolien H. M. van Deurzen, P. J. van Diest, J.A.A.M. van Dijck, Eddy Adang, J.W.R. Nortier, Emiel J. Rutgers, C. Seynaeve, Marian B. E. Menke‐Pluymers, Peter Bult, Vivianne C. G. Tjan‐Heijnen
201226
11
Cytotoxic therapy for the elderly with metastatic breast cancer: A review on safety, pharmacokinetics and efficacy
European Journal of Cancer ·Paul Hamberg, Jaap Verweij, C. Seynaeve
200722
12
5-HT3 receptor antagonists, a new approach in emesis
Anti-Cancer Drugs ·C. Seynaeve, Jaap Verweij, PHM de Mulder
199120
13
Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients.
PubMed ·L.C. Verhoog, E. Berns, Cecile T.M. Brekelmans, C. Seynaeve, E.J. Meijers-Heijboer, J.G.M. Klijn
200020
14
Randomised phase II trial of carboplatin and iproplatin in advanced urothelial cancer
European Journal of Cancer and Clinical Oncology ·Ronald de Wit, Margot Tesselaar, T.C. Kok, C. Seynaeve, C. J. Rodenburg, Jaap Verweij, P.A. Helle, G. Stoter
199120
15
High-dose chemotherapy in adult sarcomas: no standard yet.
PubMed ·C. Seynaeve, Jaap Verweij
199917
16
671 Phase III study comparing AT (Adriamycin, Docetaxel) to FAC (Fluorouracil, Adriamycin, Cyclophosphamide) as first-line chemotherapy (CT) in patients with metastatic breast cancer (MBC)
European Journal of Cancer Supplements ·M. Bontenbal, J.J. Braun, G.J. Creemers, A C de Boer, Jan Janßen, Mark Leys, Kristel L. Schothorst, P.I.M. Schmitz, J.J. Bokma, C. Seynaeve
200316
17
Randomized study comparing efficacy/toxicity of monotherapy trastuzumab followed by monotherapy docetaxel at progression, and combination trastuzumab/docetaxel as first-line chemotherapy in HER2-neu positive, metastatic breast cancer (MBC) (HERTAX study)
Journal of Clinical Oncology ·M. Bontenbal, C. Seynaeve, Jacqueline M. Stouthard, M. Bos, Hans‐Joachim Braun, F. Erdkamp, Gert van Deijk, P.I.M. Schmitz, I. Van der Stelt-Frissen, Paul Hamberg, J.G.M. Klijn
200815
18
Pathophysiology of cytotoxic drug-induced emesis: far from crystal-clear
Pharmacy World & Science ·C. Seynaeve, P.H.M. de Mulder, Jaap Verweij
199112
19
Micrometastases and isolated tumor cells: relevant and robust or rubbish? (MIRROR): preliminary results of the MIRROR study from the Dutch breast cancer trialists' group (BOOG).
Cancer Research ·Maaike de Boer, CH van Deurzen, JA van Dijck, GF Borm, PJ van Diest, E. M. Adang, HW Nortier, EJ Rutgers, C. Seynaeve, M. Menke-Pluymers, Peter Bult, VC Tjan-Heijnen
20099
20
Survival and Tumour Characteristics of Breast-Cancer Patients with Germline Mutations of BRCA1
Obstetrical & Gynecological Survey ·L.C. Verhoog, Cecile T.M. Brekelmans, C. Seynaeve, L. M. C. van den Bosch, G Dahmen, A.N. van Geel, Madeleine M.A. Tilanus‐Linthorst, C.C.M. Bartels, A. Wagner, AMW van den Ouweland, Peter Devilee, E.J. Meijers-Heijboer, J.G.M. Klijn
19989

About C. Seynaeve

C. Seynaeve is a scholar working on Genetics, Pulmonary and Respiratory Medicine, Oncology, Surgery and Cancer Research, having authored 37 papers that have together received 668 indexed citations. Recurring topics across this work include BRCA gene mutations in cancer (9 papers), Cancer Treatment and Pharmacology (7 papers), Sarcoma Diagnosis and Treatment (6 papers), Breast Cancer Treatment Studies (6 papers), Nausea and vomiting management (5 papers), Advanced Breast Cancer Therapies (4 papers), Estrogen and related hormone effects (4 papers) and Vascular Tumors and Angiosarcomas (4 papers). The work is most often cited by research in Oncology (237 citations), Cancer Research (129 citations), Genetics (180 citations), Pulmonary and Respiratory Medicine (130 citations) and Gastroenterology (22 citations). C. Seynaeve has collaborated with scholars based in Netherlands, United States and United Kingdom. Frequent co-authors include Jaap Verweij, M. Bontenbal, PHM de Mulder, Ronald de Wit, J.G.M. Klijn, Rolf H. Sijmons, Aad Tibben, Iris van Oostrom, A Bröcker-Vriends and H.J. Duivenvoorden. Their work appears in journals such as European Journal of Cancer, Cancer Research, Journal of Clinical Oncology, Annals of Oncology and Acta Oncologica.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Winston UenoBreakdown of academic impact, for papers by Anni Ravnsbæk JensenBreakdown of academic impact, for papers by Hye Sook HanBreakdown of academic impact, for papers by Kentaro NakaoBreakdown of academic impact, for papers by Erna BuschBreakdown of academic impact, for papers by Jill D. TrimbathBreakdown of academic impact, for papers by A.M. ThompsonBreakdown of academic impact, for papers by Sergio Di PietroBreakdown of academic impact, for papers by Rakesh ChopraBreakdown of academic impact, for papers by Anne S. Quante